newsfilter
← Latest News
GlobeNewswire·

CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis

AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar's accelerated